Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, China.
Shanghai Engineering Research Center of Proton and Heavy Ion Radiation Therapy, Shanghai, China.
Sci Rep. 2019 Mar 12;9(1):4259. doi: 10.1038/s41598-019-39241-y.
To investigate the safety and efficacy of salvage carbon-ion radiation therapy (CIRT) in patients with locoregionally recurrent head and neck malignancies. One hundred and forty-one patients with locally recurrent head and neck malignancies previously treated with radiotherapy were salvaged using intensity-modulated carbon-ion radiation therapy (CIRT). The median dose was 60 Gray-Equivalent (GyE) (range 50-69 GyE, 2.0~3.5 GyE/daily fraction). All patients completed planned CIRT except for one. With a median follow-up time of 14.7 (range 1.6-36.4) months, the 1-year overall survival rate was 95.9%. Local, regional, and distant progression free survival rates were 84.9% and 97.7%, and 96%, respectively. Grade 3 or higher acute and late toxicities were observed in 7.1% of the patients. Ten patients developed mucosal necrosis and 4 of these patients deceased. Due to its physical and biological characteristics, CIRT appeared to be an acceptable treatment option for patients with locoregionally recurrent head and neck malignancies after previous radiotherapy. Treatment-induced adverse effects and early response to CIRT were both favorable. Longer follow-up is needed to evaluate the long-term outcome in terms of disease control, survival, as well as potential late effects.
探讨局部复发性头颈部恶性肿瘤患者挽救性碳离子放射治疗（CIRT）的安全性和有效性。对 141 例局部复发性头颈部恶性肿瘤患者进行挽救性调强碳离子放射治疗（CIRT）。中位剂量为 60 Gray-Equivalent（GyE）（范围 50-69 GyE，2.0~3.5 GyE/daily fraction）。除 1 例患者外，所有患者均完成计划的 CIRT。中位随访时间为 14.7（范围 1.6-36.4）个月，1 年总生存率为 95.9%。局部、区域和远处无进展生存率分别为 84.9%、97.7%和 96%。7.1%的患者出现 3 级或以上急性和迟发性毒性。10 例患者发生黏膜坏死，其中 4 例患者死亡。由于其物理和生物学特性，CIRT 似乎是局部复发性头颈部恶性肿瘤患者在先前放疗后的一种可接受的治疗选择。CIRT 诱导的不良反应和早期反应均良好。需要更长时间的随访来评估疾病控制、生存以及潜在迟发性效应方面的长期结果。
